MBX Biosciences (MBX) Common Equity (2023 - 2026)

MBX Biosciences (MBX) has 4 years of Common Equity data on file, last reported at $437.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 85.95% year-over-year to $437.8 million; the trailing twelve-month figure through Mar 2026 stood at $437.8 million (up 85.95% YoY), and the FY2025 full-year result was $369.2 million, up 43.42% from the prior year.
• Common Equity improved to $437.8 million in Q1 2026, from $369.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $437.8 million in Q1 2026 to a low of -$97.9 million in Q2 2024.
• A 4-year average of $169.1 million and a median of $235.4 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 518.66% in 2024 and surged 42.81% in 2025, its largest moves.
• Tracing MBX's Common Equity over 4 years: stood at -$72.5 million in 2023, then soared by 455.25% to $257.4 million in 2024, then jumped by 43.42% to $369.2 million in 2025, then grew by 18.56% to $437.8 million in 2026.
• Business Quant data shows MBX's Common Equity at $437.8 million in Q1 2026, $369.2 million in Q4 2025, and $387.5 million in Q3 2025.